Gene expression profile analysis identifies metastasis and chemoresistance-associated genes in epithelial ovarian carcinoma cells

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-13

  Zhu, Liancheng ^a   Hu, Zhenhua ^a   Liu, Juanjuan ^a   Gao, Jian ^a   Lin, Bei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance associated genes; Epithelial ovarian carcinoma; FOXP1; Gene expression profile; Metastasis associated gene; Microarray

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORKHEAD BOX P1; GERMINAL CENTER EXPRESSED TRANSCRIPT 2; GLYCINE TRANSFER RNA LIGASE; OLIGONUCLEOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; SORTING NEXIN 29; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CELL DIFFERENTIATION; CLUSTER ANALYSIS; COC1 CELL LINE; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HO8910 CELL LINE; HUMAN; HUMAN CELL; HUMAN GENOME; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RMG I C CELL LINE; STAINING; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENETICS; KAPLAN MEIER METHOD; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84920137292     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0426-5     Document Type: Article

References (52)

1. Liu CM. Cancer of the ovary. N Engl J Med. 2005;352:1268–9; author reply-9.
2. Iwamori M, Tanaka K, Kubushiro K, Lin B, Kiguchi K, Ishiwata I, et al. Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene. Cancer Sci. 2005;96:26–30.
3. Lin B, Hao YY, Wang DD, Zhu LC, Zhang SL, Saito M, et al. Transfection of alpha1, 2-fucosyltransferase gene increases the antigenic expression of Lewis y in ovarian cancer cell line RMG-I. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae. 2008;30:284–9.
4. Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y, et al. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep. 2010;23:833–41.
5. Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang CZ, et al. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie. 2010;92:852–7.
6. Gao S, Liu Q, Wang X, Lin B, Zhang S. Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med Oncol. 2010;27:960–7.
7. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, et al. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res CR. 1999;18:233–9.
8. Gao J, Hu Z, Liu D, Liu J, Liu C, Hou R, et al. Expression of Lewis y antigen and integrin alphav, beta3 in ovarian cancer and their relationship with chemotherapeutic drug resistance. J Exp Clin Cancer Res CR. 2013;32:36.
9. Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J, et al. Elevated levels of Lewis y and integrin alpha5beta1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 2012;13:15588–600.
10. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007;11:955–65.
11. Diaz-Montana JJ, Diaz-Diaz N. Development and use of the Cytoscape app GFD-Net for measuring semantic dissimilarity of gene networks. F1000 Res. 2014;3:142.
12. Pan Z, Shen Y, Ge B, Du C, McKeithan T, Chan WC. Studies of a germinal centre B-cell expressed gene, GCET2, suggest its role as a membrane associated adapter protein. Br J Haematol. 2007;137:578–90.
13. Schenten D, Egert A, Pasparakis M, Rajewsky K. M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice. Blood. 2006;107:4849–56.
14. Natkunam Y, Lossos IS, Taidi B, Zhao S, Lu X, Ding F, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood. 2005;105:3979–86.
15. Lu X, Kazmierczak K, Jiang X, Jones M, Watt J, Helfman DM, et al. Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin. FEBS J. 2011;278:1922–31.
16. Romero-Camarero I, Jiang X, Natkunam Y, Lu X, Vicente-Duenas C, Gonzalez-Herrero I, et al. Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun. 2013;4:1338.
17. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105:122–9.
18. McWilliams R, Highsmith WE, Rabe KG, de Andrade M, Tordsen LA, Holtegaard LM, et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut. 2005;54:1661–2.
19. Zhang JT, Jiang XH, Xie C, Cheng H, Da Dong J, Wang Y, et al. Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta. 2013;1833:2961–9.
20. Peng X, Wu Z, Yu L, Li J, Xu W, Chan HC, et al. Overexpression of cystic fibrosis transmembrane conductance regulator (CFTR) is associated with human cervical cancer malignancy, progression and prognosis. Gynecol Oncol. 2012;125:470–6.
21. Warren N, Holmes JA, Al-Jader L, West RR, Lewis DC, Padua RA. Frequency of carriers of cystic fibrosis gene among patients with myeloid malignancy and melanoma. BMJ (Clinical research ed). 1991;302:760–1.
22. Qiao D, Yi L, Hua L, Xu Z, Ding Y, Shi D, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene 5T allele may protect against prostate cancer: a case-control study in Chinese Han population. J Cyst Fibros. 2008;7:210–4.
23. Li Y, Sun Z, Wu Y, Babovic-Vuksanovic D, Li Y, Cunningham JM, et al. Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. Lung Cancer (Amsterdam, Netherlands). 2010;70:14–21.
24. Li C, Schuetz JD, Naren AP. Tobacco carcinogen NNK transporter MRP2 regulates CFTR function in lung epithelia: implications for lung cancer. Cancer Lett. 2010;292:246–53.
25. Pagano MA, Tibaldi E, Gringeri E, Brunati AM. Tyrosine phosphorylation and liver regeneration: a glance at intracellular transducers. IUBMB Life. 2012;64:27–35.
26. Fischer DC, Noack K, Runnebaum IB, Watermann DO, Kieback DG, Stamm S, et al. Expression of splicing factors in human ovarian cancer. Oncol Rep. 2004;11:1085–90.
27. Ouyang YQ, zur Hausen A, Orlowska-Volk M, Jager M, Bettendorf H, Hirschfeld M, et al. Expression levels of hnRNP G and hTra2-beta1 correlate with opposite outcomes in endometrial cancer biology. Int J Cancer J Int du Cancer. 2011;128:2010–9.
28. Nasim MT, Chernova TK, Chowdhury HM, Yue BG, Eperon IC. HnRNP G and Tra2beta: opposite effects on splicing matched by antagonism in RNA binding. Hum Mol Genet. 2003;12:1337–48.
29. Shin KH, Kang MK, Kim RH, Christensen R, Park NH. Heterogeneous nuclear ribonucleoprotein G shows tumor suppressive effect against oral squamous cell carcinoma cells. Clin Cancer Res. 2006;12:3222–8.
30. Shin KH, Kim RH, Kim RH, Kang MK, Park NH. hnRNP G elicits tumor-suppressive activity in part by upregulating the expression of Txnip. Biochem Biophys Res Commun. 2008;372:880–5.
31. Shin KH, Kim RH, Yu B, Kang MK, Elashoff D, Christensen R, et al. Expression and mutation analysis of heterogeneous nuclear ribonucleoprotein G in human oral cancer. Oral Oncol. 2011;47:1011–6.
32. Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010;285:39953–64.
33. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42:751–4.
34. Long QZ, Du YF, Ding XY, Li X, Song WB, Yang Y, et al. Replication and fine mapping for association of the C2orf43, FOXP4, GPRC6A and RFX6 genes with prostate cancer in the Chinese population. PLoS One. 2012;7:e37866.
35. Haiman CA, Han Y, Feng Y, Xia L, Hsu C, Sheng X, et al. Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLoS Genet. 2013;9:e1003419.
36. Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012;72:399–409.
37. Green MR, Gandhi MK, Courtney MJ, Marlton P, Griffiths L. Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma. Leuk Res. 2009;33:1699–702.
38. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 2012;138:230–5.
39. Santos ME, Athanasiadis A, Leitao AB, DuPasquier L, Sucena E. Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily. Mol Biol Evol. 2011;28:237–47.
40. Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology. 2010;57:73–80.
41. Ijichi N, Ikeda K, Horie-Inoue K, Inoue S. FOXP1 and estrogen signaling in breast cancer. Vitam Horm. 2013;93:203–12.
42. Bates GJ, Fox SB, Han C, Launchbury R, Leek RD, Harris AL, et al. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat. 2008;111:453–9.
43. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH. Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol. 2006;19:9–16.
44. Takayama K, Horie-Inoue K, Ikeda K, Urano T, Murakami K, Hayashizaki Y, et al. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun. 2008;374:388–93.
45. Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Fussel S, et al. Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer Invest. 2011;29:123–9.
46. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L, Carter DR. Pseudogenes pseudo-functional or key regulators in health and disease. RNA (New York, NY). 2011;17:792–8.
47. Balasubramanian S, Zheng D, Liu YJ, Fang G, Frankish A, Carriero N, et al. Comparative analysis of processed ribosomal protein pseudogenes in four mammalian genomes. Genome Biol. 2009;10:R2.
48. Li W, Yang W, Wang XJ. Pseudogenes: pseudo or real functional elements? J Genet Genom. 2013;40:171–7.
49. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033–8.
50. Han YJ, Ma SF, Yourek G, Park YD, Garcia JG. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J. 2011;25:2305–12.
51. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell. 2012;149:1622–34.
52. Chiefari E, Iiritano S, Paonessa F, Le Pera I, Arcidiacono B, Filocamo M, et al. Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes. Nature Commun. 2010;1:40.